Eli Lilly (LLY) maintains strong fundamental momentum driven by its dominant market position in GLP-1 medications, with analysts projecting the stock could reach $1,414 by December 2027 based on expected 26% annual revenue growth.
- The stock traded at $1,035.70 and has delivered a 37% return over the past year.
- Fundamental strength is underscored by Q3 revenue surging 54% year-over-year.
- Future growth is tied to the successful launches of the oral GLP-1 orforglipron and the triple agonist retatrutide, both anticipated in 2026.